Targeting the WNT Signaling Pathway in Cancer Therapeutics

  • Tai D
  • Wells K
  • Arcaroli J
  • et al.
120Citations
Citations of this article
90Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

© AlphaMed Press 2015. The WNT signaling cascade is integral in numerous biological processes including embryonic development, cell cycle regulation, inflammation, and cancer. Hyperactivation of WNT signaling secondary to alterations to varying nodes of the pathway have been identified in multiple tumor types. These alterations converge into increased tumorigenicity, sustained proliferation, and enhanced metastatic potential. This review seeks to evaluate the evidence supporting the WNT pathway in cancer, the therapeutic strategies in modulating this pathway, and potential challenges in drug development. Implications for Practice: The WNT signaling cascade is integral in numerous biological processes, including cell cycle regulation and cancer. Alterations in WNT signaling have been identified in numerous tumor types, and in recent years, numerous WNT pathway modulators have been tested in preclinical studies. These agents are now being investigated in the clinical arena, and this review describes the WNT pathway and therapeutics currently in development.

Cite

CITATION STYLE

APA

Tai, D., Wells, K., Arcaroli, J., Vanderbilt, C., Aisner, D. L., Messersmith, W. A., & Lieu, C. H. (2015). Targeting the WNT Signaling Pathway in Cancer Therapeutics. The Oncologist, 20(10), 1189–1198. https://doi.org/10.1634/theoncologist.2015-0057

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free